PROC (procapsgroup.com) Market Value to Book Value Ratio

Official company branding of Procaps Group (PROC)

Procaps Group S.A. revenue predictability is based on multi-year contracts with industry leaders. The historical relationship between market cap and book value demonstrates the impact of liquidity on asset valuation, where the indicator settled at 6.60. The CDMO B2B model guarantees high margins and FCF inflows, although compliance costs limit net profit growth during capacity scaling.

PROC Procaps Group Corp: Market Value to Book Value in the range 07/04/2022 - 12/31/2024

Financial and market metric breakdowns for Procaps Group (PROC)

- price and consensus price forecast:
Stock Price Procaps Group S.A.|PROC - Consensus Target
- market capitalization data:
Market Value Procaps Group SA|PROC - Full Business Value
- book capitalization data:
Book Value per Share Procaps|PROC - Accounting Value of Company|Market Capitalization to Book Value Ratio procapsgroup.com|PROC - Company Total Assets
- debt and liquidity data:
Debt to Equity Procaps Group S.A.|PROC - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Procaps Group SA|PROC - Company Total Debt|Debts to Book Capitalization Procaps Group SA
Initial company analysis:Procaps Group S.A. - PROC
Original product of Procaps Group SA

When assessing the asset quality of Procaps Group S.A. (PROC), it is essential to align market expectations with the actual value of the business. This price-to-book ratio reflects the relationship between current market capitalization and the issuer's net assets. The metric reveals whether shares are overvalued or undervalued relative to their balance sheet base. For an innovator in drug delivery, a high premium is justified by investments in R&D and automation, which confirms the market value of the company's intellectual capital.

Main competitors

HLN (Haleon plc) - Market Capitalization to Book Value Ratio|KVUE (kenvue.com) - Market Cap to Net Assets Ratio|Market Value to Book Value Ratio Verona Pharma VRNA|Market Capitalization to Net Assets Jyong Biotech Limited|Ligand Pharma (LGND) - Market Capitalization to Book Value Ratio|Market Value to Book Value Amneal Corp (AMRX)|Market Capitalization to Book Value Ratio PRGO (Perrigo Company plc)|alvotech.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Liquidia (LQDA)|GLPG: Market Value to Book Value|ANIP (ANI Pharma) - Market Value to Book Value Ratio|Afrezza (MNKD) - Market Cap to Net Assets Ratio|AMPH (Amphastar Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio pacira.com (PCRX)|ARS Pharmaceuticals, Inc. (SPRY) - Market Cap to Net Assets Ratio|Market Value to Book Value TBPH (Theravance Biopharma Inc)|AQST: Market Value to Book Value Ratio|SCPH - Market-to-Book Ratio|Market Cap to Net Assets Ratio Tectonic TECX|TNXP - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio sxtchina.com SXTC|Eupraxia Pharmaceuticals Inc. (EPRX) - Market Value to Book Value|Market Capitalization to Book Value Ratio BHST (BioHarvest)|Market-to-Book Ratio EXOZ|Oramed Pharmaceuticals (ORMP) - Market Value to Book Value Ratio|Market Value to Book Value ENTX (enterabio.com)|MindWalk Holdings Inc. (HYFT) - Market Value to Book Value Ratio|ABVC BioPharma Inc. - Market Capitalization to Net Assets|Market Value to Book Value Ratio Cumberland Pharma (CPIX)|QNTM: Market Value to Book Value|Market Value to Book Value Ratio FGEN|telomirpharma.com (TELO) - Market-to-Book Ratio|Market Capitalization to Book Value Ratio RANI|Market Cap to Net Assets Ratio Synergy CHC Corporation|Market Capitalization to Book Value Ratio RLYB|Market Capitalization to Book Value Ratio LEXX (lexariabioscience.com)|Pulmatrix, Inc. (PULM) - Market Value to Book Value Ratio|Pheton Holdings Limited - Market Capitalization to Net Assets|Market Value to Book Value Ratio APM (Aptorum)|Lyra Therapeutics Inc. (LYRA) - Market Capitalization to Book Value|Market Cap to Net Assets Ratio Impact BioMedical IBO|TNF Pharmaceuticals, Inc. (TNFA) - Market Value to Book Value|cbdMD Inc. - Market Capitalization to Book Value Ratio|Market Value to Equity Ratio PRFX|Altamira Therapeutics (CYTO) - Market Value to Book Value Ratio|Market Value to Book Value LIPO (Lipella Pharmaceuticals Inc)|OPTN: Market Value to Book Value Ratio|PIRS - Market-to-Book Ratio|Petros Pharmaceuticals - Market Cap to Net Assets Ratio|QLI: Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio ACELYRIN (SLRN)|Market Capitalization to Net Assets TFF Pharmaceuticals Inc.